Search

Your search keyword '"Juha E.K. Hartikainen"' showing total 6 results
Start Over Author "Juha E.K. Hartikainen"
6 results on '"Juha E.K. Hartikainen"'

1. Temporal trends of catheter ablation procedures in patients with atrial fibrillation and atrial flutter: A nationwide cohort study

Author

Antti Lappalainen, Juha E.K. Hartikainen, Konsta Teppo, Olli Halminen, Aapo L. Aro, Rasmus Siponen, Janne Virrankorpi, Annukka Marjamaa, Birgitta Salmela, Jukka Putaala, Pirjo Mustonen, Miika Linna, Jari Haukka, K.E. Juhani Airaksinen, and Mika Lehto

Subjects
Atrial fibrillation, Atrial flutter, Catheter ablation, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Background: Catheter ablation is a well-established treatment to prevent atrial fibrillation (AF) and atrial flutter (AFL) recurrences and to relieve symptoms, whereas pacemaker implantation and atrioventricular node (AVN) ablation is used for rate control when medical therapy fails. Aims: We investigated temporal trends and patient characteristics in catheter ablation procedures for AF, AFL and AVN in Finland between 2012–2018. Methods: Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) is a registry-based study including all patients with AF or AFL in Finland between 2012–2018. Results: The number of patients with AF or AFL diagnosis in Finland increased from 185 057 to 243 802 between 2012–2018 and a total of 8954 first-time catheter ablation procedures were performed. Of them, 4909 (54.8 %) were AF ablations, 2731 (30.5 %) AFL ablations and 1314 (14.7 %) AVN ablations. The procedural numbers increased from 457/year to 934/year for AF, from 223/year to 553/year for AFL and from 114/year to 238/year for AVN. Altogether, 0.65% of all patients with diagnosed AF or AFL underwent AF, AFL or AVN ablation in 2018. The mean age of the patients increased in all ablation groups. Patients undergoing AF and AFL ablations were predominantly men (69.7 % and 74.6 % respectively) whereas patients undergoing AVN ablation were more often women (56.9%). Conclusions: The use of catheter ablation more than doubled during 2012–2018 and the increase was particularly seen in the elderly patients. Nevertheless, only a minority of AF and AFL patients were treated with catheter ablations.

Published
2024
Full Text
View/download PDF

2. Testing of Common Electromagnetic Environments for Risk of Interference with Cardiac Pacemaker Function

Author

Maria Tiikkaja, Aapo L. Aro, Tommi Alanko, Harri Lindholm, Heli Sistonen, Juha E.K. Hartikainen, Lauri Toivonen, Jukka Juutilainen, and Maila Hietanen

Subjects
cardiac pacemakers, electromagnetic fields, occupational exposure, risk assessment, Public aspects of medicine, RA1-1270
Abstract

Background: Cardiac pacemakers are known to be susceptible to strong electromagnetic fields (EMFs). This in vivo study investigated occurrence of electromagnetic interference with pacemakers caused by common environmental sources of EMFs. Methods: Eleven volunteers with a pacemaker were exposed to EMFs produced by two mobile phone base stations, an electrically powered commuter train, and an overhead high voltage transmission lines. All the pacemakers were programmed in normal clinically selected settings with bipolar sensing and pacing configurations. Results: None of the pacemakers experienced interference in any of these exposure situations. However, often it is not clear whether or not strong EMFs exist in various work environments, and hence an individual risk assessment is needed. Conclusions: Modern pacemakers are well shielded against external EMFs, and workers with a pacemaker can most often return to their previous work after having a pacemaker implanted. However, an appropriate risk assessment is still necessary after the implantation of a pacemaker, a change of its generator, or major modification of its programming settings.

Published
2013
Full Text
View/download PDF

3. Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation in the Emergency Department: The SPECTRUM Study

Author

Johan-Emil Bager, Alfonso Martín, José Carbajosa Dalmau, Alexander Simon, José L. Merino, Beate Ritz, and Juha E.K. Hartikainen

Subjects
Adult, Treatment Outcome, Atrial Fibrillation, Electric Countershock, Humans, Pharmacology (medical), Emergency Service, Hospital, Cardiology and Cardiovascular Medicine, Anti-Arrhythmia Agents
Abstract

Introduction: Intravenous vernakalant is a therapeutic option for symptomatic, recent-onset atrial fibrillation (AF). This secondary analysis from the large SPECTRUM study assessed the safety and effectiveness of vernakalant when used in the emergency department setting (ED group) or in an inpatient hospital setting (non-ED group). Methods: This post hoc analysis of the international, observational, post-authorization SPECTRUM study included 1,289 and 720 recent-onset AF episodes in adults in the ED and non-ED groups, respectively. Safety endpoints included the evaluation of pre-defined health outcomes of interest (HOIs) and other serious adverse events (SAEs) during vernakalant treatment and during the first 24 h after the last infusion. Effectiveness endpoints comprised the rate of successful vernakalant cardioversion, the time from the start of the vernakalant infusion to cardioversion, and the length of hospital stay. Data were analysed using descriptive statistics. Results: The safety profile of vernakalant was similar in the ED and non-ED groups. In the ED group, 12 pre-defined HOIs were reported in 11 patients (0.9%); all but one occurred within 2 h after start of the first infusion. These events comprised nine significant bradycardia cases, of which one was associated with transient hypotension and three with sinus arrest, and 2 cases of atrial flutter with 1:1 conduction. Five other SAEs were reported. All patients with vernakalant-related events recovered without sequelae. No Torsade de Pointes, ventricular fibrillation, or deaths occurred. Successful cardioversion was reported in 67.8% (95% confidence interval: 65.2–70.4) and 66.4% (62.5–70.1) of episodes, with a median time to conversion of 11.0 and 10.0 min in the ED and non-ED groups, respectively. Patients had a median length of hospital stay of 7.4 h and 17.1 h in the ED and non-ED groups, respectively. Conclusion: Intravenous vernakalant was well tolerated with similar cardioversion rates in patients treated in the ED or non-ED setting and does not require admission to a coronary care unit or intensive care unit. First-line treatment with vernakalant could allow an early discharge in patients with recent-onset AF treated in the ED.

Published
2022
Full Text
View/download PDF

4. Contributors

Author

Aref Albakri, Soufian T. AlMahameed, Irena Andršová, Samuel J. Asirvatham, Jennifer N. Avari Silva, Ljuba Bacharova, Giuseppe Bagliani, Rody Barakat, Michel M. Barakat, Valentina Barletta, Petra Barthel, Markéta Bébarová, Hiroko Beck, Bernard Belhassen, Girish Bende, Anna Berkefeld, Ulrika Birgersdotter-Green, Ksenia Blinova, Carina Blomström-Lundqvist, Maria Grazia Bongiorni, Thomas Brand, Raffaele Bugiardini, T. Jared Bunch, Alessandro Castiglione, Edina Cenko, Sofia Chatzidou, Jennifer Chee, Mihail G. Chelu, Shih Ann Chen, Giuseppe Ciconte, Anne B. Curtis, Stephanie Curtis, Iwona Cygankiewicz, Aarti S. Dalal, John D. Day, Veronica Della Tommasina, Abhishek J. Deshmukh, Polychronis Dilaveris, Roberto Di Summa, Mehmet Dogan, Jun Dong, Jeanne du Fay de Lavallaz, Lee L. Eckhardt, Elena Efimova, Sabine Ernst, Ameenathul M. Fawzy, Fiorenzo Gaita, Libet Garber, Christine Garnett, Georgios Georgiopoulos, Anne M. Gillis, Carla Giustetto, M. Cecilia Gonzalez Corcia, Moti Haim, Brian P. Halliday, Mohamed H. Hamdan, Daniel J. Hammersley, Juha E.K. Hartikainen, Kristina H. Haugaa, M. Anette E. Haukilahti, Arto J. Hautala, Kateřina Helánová, Katerina Hnatkova, Yu-Feng Hu, Xiao Hu, David Hurley, Sei Iwai, Victoria Jacobs, Jason T. Jacobson, Cynthia A. James, Hongying Jiang, Camelle Jones, Richard E. Jones, M. Juhani Junttila, Alan H. Kadish, Laura Karavirta, Saima Karim, Dilip Karnad, Anne Karunatilleke, Elizabeth S. Kaufman, Tuomas V. Kenttä, Louise Kezerle, Fouad M. Khalil, Thomas Klingenheben, M. Kloosterman, Christos Kontogiannis, Gurukripa N. Kowlgi, Anne M. Kroman, Valentina Kutyifa, Rachel Lampert, Jari Laukkanen, Hyon Jae Lee, Pavel Leinveber, Ida S. Leren, Fabio V. Lima, Cecilia Linde, Emanuela T. Locati, Peter W. Macfarlane, Hamish Maclachlan, Timo H. Mäkikallio, Marek Malik, Olivia Manfrini, Qussay Marashly, Eleni Margioula, James A. McCaffrey, Nandini S. Mehra, Anat Milman, Sarah Moharem-Elgamal, Nebojša Mujović, Darbhamulla V. Nagarajan, Petr Nemec, Tomáš Novotný, Louisa O'Neill, Katja E. Odening, Gopi Krishna Panicker, Carlo Pappone, Kristen K. Patton, Michele M. Pelter, Mattia Peyracchia, Tratjana Potpara, Benjamin E. Powell, Bjerregaard Preben, Andrea Sarkozy, Birke Schneider, Luca Segreti, Kimberly A. Selzman, Sanjay Sharma, Martina Šišáková, D.A. Spears, Francesco Raffaele Spera, Lenka Špinarová, Phyllis K. Stein, Kathleen Stergiopoulos, Christian Sticherling, Graham Stuart, Alan M. Sugrue, Emma Svennberg, Hiroshi Tada, Konstantinos Tampakis, Larisa G. Tereshchenko, Henri Terho, Anneline S.J.M. te Riele, Jani T. Tikkanen, Ondřej Toman, Elisabetta Toso, Cynthia M. Tracy, Danijela Trifunovic, James M.A. Turner, Vaibhav R. Vaidya, Isabelle C. Van Gelder, Tharni Vasavan, Richard L. Verrier, Granit Veseli, Jose Vicente, Catherine Williamson, Wendy W. Wu, Gregory YH. Lip, Arwa Younis, Markus Zabel, Zafraan Zathar, Jessica K. Zegre-Hemsey, Nan Zheng, and Giulio Zucchelli

Published
2020
Full Text
View/download PDF

6. Heart rate dynamics in coronary artery disease

Author

Juha E.K. Hartikainen

Subjects
Coronary artery disease, medicine.medical_specialty, Framingham Risk Score, business.industry, Physiology (medical), Internal medicine, Heart rate, Cardiology, Medicine, Myocardial infarction, business, medicine.disease, Pathology and Forensic Medicine
Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results